Abstract
Background: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors.
Methods & Results: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included.
Conclusion: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients.
Keywords: Chemoprevention, skin carcinomas, solid organ transplantation, immunosuppression, nicotinamide, retinoids.
Current Medicinal Chemistry
Title:Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Volume: 25 Issue: 6
Author(s): Paola Savoia*, Elisa Zavattaro and Ottavio Cremona
Affiliation:
- San Raffaele Scientific Institute, Vita Salute San Raffaele University, v. Olgettina 58, 20132 Milano,Italy
Keywords: Chemoprevention, skin carcinomas, solid organ transplantation, immunosuppression, nicotinamide, retinoids.
Abstract: Background: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors.
Methods & Results: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included.
Conclusion: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients.
Export Options
About this article
Cite this article as:
Savoia Paola*, Zavattaro Elisa and Cremona Ottavio , Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients, Current Medicinal Chemistry 2018; 25(6) . https://dx.doi.org/10.2174/0929867324666171003123056
DOI https://dx.doi.org/10.2174/0929867324666171003123056 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Apoptosis and Apoptosis-Based Therapy in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Current Signal Transduction Therapy Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Drug Delivery Letters Formulation, Characterization and In vitro Cytotoxicity of 5-Fluorouracil Loaded Polymeric Electrospun Nanofibers for the Treatment of Skin Cancer
Recent Patents on Nanotechnology Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets